linrodostat: Clinical Trials

11 trials of linrodostat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 4 terminated, 1 active not recruiting, 1 withdrawn. 11 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 5, Terminated 4, Active not recruiting 1, Withdrawn 1
Phase 14Completed 3, Terminated 1

Follow linrodostat: new trials by email Literature Review of linrodostat trials Research Report on linrodostat

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment
Nivolumab, BMS- 986205 - Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
Phase 2Active not recruitingMemorial Sloan Kettering Cancer Center242019-09-242026-10-16
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
Nivolumab, BMS-986205, Ipilimumab - Melanoma Stage III, Melanoma Stage IV
Phase 2WithdrawnDana-Farber Cancer Institute2019-09-062020-02-05
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Nivolumab, IDO1 Inhibitor BMS-986205, Therapeutic Conventional Surgery - Lip, Oral Cavity Squamous Cell Carcinoma
Phase 2TerminatedThomas Jefferson University652019-04-092026-10-19
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
BMS-986205, Nivolumab - Advanced Cancer
Phase 1 / Phase 2CompletedBristol-Myers Squibb122018-12-312022-02-28
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer
IDO1 Inhibitor BMS-986205, Nivolumab - Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Phase 1 / Phase 2TerminatedEdward Kim82018-10-162026-07-29
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Nivolumab, BCG, BMS-986205 - Urinary Bladder Neoplasms
Phase 2TerminatedBristol-Myers Squibb1422018-08-022023-06-01
An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread
Relatlimab, Nivolumab, BMS-986205 - Advanced Cancer
Phase 1 / Phase 2CompletedBristol-Myers Squibb2292018-05-302026-04-06
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Nivolumab, Ipilimumab, Relatlimab - Advanced Cancer
Phase 2CompletedBristol-Myers Squibb1822017-02-022022-12-19
A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer
Nivolumab, Ipilimumab, Relatlimab - Advanced Gastric Cancer
Phase 2CompletedBristol-Myers Squibb1902016-11-292023-06-09
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
Nivolumab, Dasatinib, Relatlimab - Advanced Cancer
Phase 2TerminatedBristol-Myers Squibb2952016-05-092021-03-22
An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread
BMS-986205, Nivolumab, Ipilimumab - Advanced Cancer, Melanoma
Phase 1 / Phase 2CompletedBristol-Myers Squibb6272016-04-142023-08-28

Conditions studied

Melanoma (2)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Squamous Cell (1)  ·  Laryngeal Diseases (1)  ·  Lymphoid Interstitial Pneumonia (1)  ·  Non-Muscle Invasive Bladder Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Urinary Bladder Neoplasms (1)

Sponsors

Bristol-Myers Squibb (7)  ·  Dana-Farber Cancer Institute (1)  ·  Edward Kim (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  Thomas Jefferson University (1)

Countries

United States (10)  ·  Australia (6)  ·  Italy (6)  ·  Canada (5)  ·  France (4)  ·  Spain (4)  ·  Switzerland (3)  ·  Austria (2)  ·  China (2)  ·  Germany (2)  ·  Israel (2)  ·  Netherlands (2)  ·  United Kingdom (2)  ·  Argentina (1)  ·  Brazil (1)

Top investigators

Adam Luginbuhl, MD (1)  ·  Chrisann Kyi, MD (1)  ·  Edward Kim, MD, PhD (1)  ·  Elizabeth I Buchbinder, MD (1)

Results publications

PMID 36328377

NIH funding

2016 (2), 2015 (1), 2017 (1), 2018 (1), P30CA093373 (1)